Neuroscience Education Institute

Dr. David Goodman discusses the gaps in ADHD treatment.

Researchers find 1 lipid class and 6 miRNAs differed significantly between different treatment groups.

It is possible to diagnose patients with ADHD as young as 2 years old.

AXS-05 significantly relieved agitation, demonstrating a change from baseline in the CMAI total score of 15.4 compared to 11.5 for the placebo.

Dr. David Goodman will present 5 times during NEI about different ADHD issues and topics.

In the study, investigators tested the impact of the study drug in a rerandomized patient population that previously received a placebo.

A large portion of communication is non-verbal.

Clinicians rated 82% of the patients receiving the study drug and 46% in the placebo group as either much improved or very much improved on the Clinical Global Impression of Improvement scale.

Attempts to use neuroimaging to screen for ADHD in the past have failed.

Both methylphenidate PRC-063 and lisdexamfetamine led to improved performances for drivers with ADHD.